

Breast Cancer: A Neglected Disease for the Majority of Affected Women Worldwide

Ophira M. Ginsburg, MD,* and Richard R. Love, MD[†]

**Women's College Research Institute, Department of Medicine, University of Toronto, and Central East Regional Cancer Program, Ontario, Canada; and* [†]*The Ohio State University Comprehensive Cancer Center, Columbus Ohio, USA, The International Breast Cancer Research Foundation, Madison, Wisconsin, USA, and The Amader Gram Breast Care Program, Khulna, Bangladesh*

■ **Abstract:** Recent progress with declines in mortality in some high-income countries has obscured the fact that for the majority of women worldwide who are newly diagnosed, breast cancer is a neglected disease in the context of other numerically more frequent health problems. For this growing majority, it is also an orphan disease, in that detailed knowledge about tumor characteristics and relevant host biology necessary to provide even basic care is absent. With the possible exception of nutritional recommendations, current international cancer policy and planning initiatives are irrelevant to breast cancer. The progress that has occurred in high-income countries has come at extraordinary fiscal expense and patient toxicity, which of themselves suggest nonrelevance to women and healthcare practitioners in middle- and low-income countries. The implications of these circumstances appear clear: if the promise of the now 60-year-old Declaration of Human Rights that the fruits of medical science accrue to all mankind is to be realized with respect to breast cancer, a basic and translational global research initiative should be launched. ■

Key Words: breast cancer, neglected disease, pharmacogenomics, population differences, tumor biology

“Orphan-adjective: Not authorized, supported, or funded; not a part of a system; isolated, abandoned; lacking a commercial sponsor.” (1)

It is anticipated that by 2010, breast cancer will be newly diagnosed in over 1.5 million women each year and that 500,000 women worldwide will die of this disease (2,3). While the incidence of new cases in some high-income countries is stabilizing, and death rates are falling, both appear to be increasing in developing countries (4–8). A majority of new cases now occur in women from low- and middle-income countries, in which the incidence is increasing by as much as 5% per year and three-fourths of global breast cancer deaths occur (9,10). In addition to aging of the now relatively young populations in low-income countries, these trends are likely to continue, as breast

cancer risk factors associated with general economic development become more prevalent. Delayed child-bearing, lower parity and decreased breast feeding, along with greater body mass index and dietary fat consumption associated with the “westernization” of diet are likely to contribute to increasing risk (11–15). To date, the only major public health intervention to address breast cancer risk concerns dietary/nutritional management.

In sum, the global breast cancer burden will be increasing in low- and middle-income countries. Barring some unlikely major public health breakthrough, the annual global mortality from this disease can only be expected to increase.

How should we frame a constructive response to this challenge? Significant media attention and high-profile fund-raising initiatives for breast cancer research in western countries have had a negligible impact on most women struggling with the disease in the rest of the world. Mammographic and MRI screening, advanced generation combination chemotherapy regimens, and targeted therapies are beyond the economic reach of most patients living where an increasing majority of the world's breast cancers

Address correspondence and reprint requests to: Ophira M. Ginsburg, MD, Women's College Research Institute, 790 Bay Street #708 Toronto Ontario M5G 1N8, Canada, or e-mail: ophira.ginsburg@utoronto.ca, ophiraginsburg@yahoo.com.

Support: NIH/NCI CA 064339 and CA 097375. The Breast Cancer Research Foundation. The International Breast Cancer Research Foundation.

DOI: 10.1111/j.1524-4741.2011.01067.x

© 2011 Wiley Periodicals, Inc., 1075-122X/11
The Breast Journal, Volume 17 Number 3, 2011 289–295

occur. More importantly, the data upon which such advances are reflected in rigorous clinical practice guidelines are based almost entirely on studies in Caucasian women of European genetic backgrounds in high-resource countries. From economic resource, public health and data perspectives, in low- and middle-income countries, breast cancer is a neglected and, indeed, an orphan disease.

In this communication, we summarize some of the evidence for population differences in breast cancer epidemiology, tumor characteristics and host biology, and argue against a “one size fits all” approach to global breast cancer control. We propose that a significant scaling up of clinical and translational research efforts in collaboration with local research teams, and with direct involvement of participants from low- and middle-income countries, is urgently needed.

BREAST CANCER EPIDEMIOLOGY: DIFFERENCES AMONG POPULATIONS

There are striking differences among populations in the age-specific incidence of breast cancer. Ethnicity and national origin are two of the stronger predictors of this variation, which represents a 5-fold difference among countries worldwide (16). Age-standardized incidence rates for breast cancer 1998–2002 were 110 (non-Hispanic Caucasians, California), 82.3 (Ontario, Canada), 41.3 (Hong Kong) and 14.7 (Jiashan, China) (3). Reasons for these differences are not well understood. There are key inter-individual and inter-group differences in the distribution of reproductive risk factors, the highly penetrant, but rare susceptibility genes *BRCA1* and *BRCA2* (17), as well as more prevalent, but lower-penetrance genes such as *CHEK2* and *FGFR* (18); but these risk factor differences provide an incomplete explanation for the marked variation in population-attributable risks for the disease. Migration studies reveal that the incidence of breast cancer changes significantly over one to two generations to reflect more closely the breast cancer risk in the adopted country (19,20). While it is difficult to tease out the causal factors to explain this observation, it seems to occur in parallel with changes in diet and other indicators of acculturation (15). Indeed, dramatic increases in breast cancer incidence have been observed in countries which have undergone massive economic development over the past 50 years, including Japan, Singapore and urban areas of China (21–25).

According to the AICR/WCRF report on “Food, Nutrition, Physical Activity and the Prevention of Cancer: a global perspective” (14) 38%, 28%, and 20% of all breast cancer cases might be prevented via a healthy diet, regular activity and maintaining a health body weight in the US, Brazil and China, respectively.

Perhaps the single most important resource in cancer epidemiology is high quality registration data, which require both accuracy and completeness of incidence and mortality reporting. More widespread cancer registration efforts are essential to evaluate differences in risk factors and natural history of all tumor types, and would allow for comparisons based on geographical regions, socioeconomic status, and levels of industrialization. Comprehensive data collection and administration are necessary components of developing and planning cancer control initiatives, appropriate allocation of resources, and prioritization of cancer health policies (26). The lack of reliable and complete census data often presents a particular challenge in low and middle-income countries.

BIOLOGY – THE TUMOR

In the first decade of the 21st century, the model of breast cancer has been redefined from that of one disease to a heterogeneous group of related diseases which vary in risk factors, natural history, growth patterns and response to treatment (27). Careful tissue specimen management and testing for hormone receptors are of pivotal importance in determining the broad parameters of appropriate treatment for patients with breast cancer – hormonal or nonhormonal, and at present should frame any discussion of breast tumor biology in different populations.

Earlier reports suggested that a majority of breast tumors from Asian women are estrogen receptor (ER) negative (28,29). However, in the past ten years, improvements in standardization and quality control of specimen handling and laboratory techniques have been implemented in many Asian centers. More recent data indicate that both pre- and postmenopausal Asian women with breast cancer, are just as likely to have ER positive tumors as Caucasians (30,31). Tran and Lawson studied ER positivity among premenopausal breast cancer cases and found a *greater* proportion of ER+ tumors in a Vietnamese cohort, compared with the comparison group of Caucasian women in Australia (31). Reliable, accurate hormone receptor testing

and reporting have immediate and direct clinical implications, as misclassification of tumors as ER negative can result in the underutilization of likely highly efficacious endocrine treatments. Specifically, Tamoxifen, which is widely available in its generic form, is an important breast cancer treatment in the neo-adjuvant, adjuvant and metastatic settings, and is affordable in most countries.

Gene expression studies using DNA microarrays have identified breast cancer subtypes, which reflect biologically distinct disease entities (32–35). Perhaps not surprisingly, there is emerging evidence of considerable variation in the gene profiles of tumors from populations of different genetic/ethnic backgrounds. Most *BRCA1*-related breast cancer, but only 15% of sporadic breast cancer in Caucasian women, appears to have the basal phenotype. However, several studies suggest that breast cancer in women of African ancestry may have a higher proportion of this subclass ([36–38] and reviewed in [39]). A high frequency of basal-like tumors was observed in a Nigerian study, where 87 of 148 (59%) breast cancer cases were both ER- and HER2- (36).

To summarize, recent data suggest that targeting the hormonal pathway may be very relevant in managing breast cancer in many populations across the spectrum of resource levels. However, beyond this, we are relatively ignorant of population differences in other tumor characteristics, which may have an impact on therapeutic efficacies and outcomes.

BIOLOGY – THE HOST

Pharmacogenomics

Decades ago, certain anti-neoplastic agents were recognized to have disproportionate levels of toxicity in certain ethnic groups, and further research has since revealed ethnic variations in the frequency of gene polymorphisms for key enzymes in drug influx, metabolism and efflux, which can affect efficacy and toxicity. In their pharmacogenetics review, Deeken and colleagues show the interrelatedness of key factors involved in drug pharmacodynamics, pharmacokinetics and pharmacogenetics (40). This is particularly relevant in medical oncology, where many drugs have a narrow therapeutic index with great potential for serious toxicity, while at the other end of the continuum, sub-optimal dosing can mean the difference between cure and death from cancer. A recent issue of the

journal *Clinical Cancer Research* (Dec 2008) dedicated five articles and an editorial to “personalized medicine,” including a review of breast cancer pharmacogenetics (41).

Specifically, data are accumulating on the impact of genetic polymorphisms in the cytochrome p450 gene and associated enzyme *CYP2D6*, which are involved in a key step in the metabolism of the selective estrogen receptor modulator, Tamoxifen. As reviewed by Sing-Huang Tan and colleagues [[41] and Table 1], there are individual and group differences in the genetically determined ability to metabolize Tamoxifen to its more active metabolites, 4-hydroxy-tamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen) which are 50 to 100 times more potent than the parent compound. Goetz and colleagues reported a clinical correlation between individuals homozygous for the *CYP2D6**4 allele and poorer disease-free and relapse-free survival as compared with heterozygotes or noncarriers of a single *4 allele (42). A second study confirmed this finding (43); however, subsequent studies have yielded conflicting results (44–46). Of particular significance, there are at least 101 known variants of *CYP2D6*, of which 26% are partially or nonfunctional in Caucasians, but 50% are reportedly partially or nonfunctional in Asians (47,48). The *CYP2D6**10 allele is a major polymorphism which results in the intermediate metabolizer phenotype, common among Asian populations, including Chinese (37–70%) (49,50), Koreans (50%) (51,52) and Japanese (40%) (52,53).

The mechanistic hypothesis which now needs to be rigorously tested is that clinical outcomes are directly related to endoxifen blood concentrations (54).

Of key relevance to the treatment of hormone receptor negative and resistant breast cancer, several classes of chemotherapeutic agents have been shown to vary markedly in metabolic genotype and phenotype. A prospective study of women treated with anthracyclines and cyclophosphamide revealed a significantly higher rate of profound neutropenia among Chinese women compared with Caucasians (55). More recently, common variants in the carbonyl reductase enzyme have been identified and have been associated with ethnic differences in the conversion of doxorubicin to its metabolite doxorubicinol, tumor response, and hematological toxicity (56).

The examples highlight the critical importance of understanding population differences in efficacy and toxicities of major cancer therapies.

Table 1. Summary of Selected Genetic Polymorphisms that Show Differences in Interethnic Frequency Distribution that may have Influence on Breast Cancer Therapeutics

Genetic polymorphisms	Drug	Interethnic genetic variation	Clinical relevance to inter ethnic differences in drug disposition
<i>CYP2D6</i>	Tamoxifen		Poor metabolizer phenotype more common in Caucasians than Asians or Black Africans. Lower levels of enzyme activity in Asians and Black Africans compared with Caucasians in the extensive metabolizer phenotype group [119]. Clinical relevance of this interethnic variation is unclear.
<i>CYP2D6*4</i>		Common in Caucasians, Rare in Asians and Black Africans.	
<i>CYP2D6*10</i>		Most common in Asians.	
<i>CYP2D6*17</i>		Rare in Caucasians.	
<i>CYP2D6*2Xn</i>		More common in Black Africans. Rare in Asians and Caucasians.	
<i>CYP2D6*2Xn</i>		More common in Ethiopians and Saudi Arabians. Rare in Caucasians, Asians, and Black Africans.	
<i>CYP3A4*1B</i>	Tamoxifen, taxanes	Commonest in Black Africans. Rare in Asians.	Has been associated with increased transcriptional activity but clinical association unclear.
<i>CYP3A5*3C</i>	Tamoxifen	Commonest in Black Africans followed by Asians. Rare in Caucasians.	Association unclear
<i>CYP19A1 Arg³⁹ variant</i>	Als	Present in 6.7% Han-Chinese Americans (42). Rare in African-Americans, Caucasian Americans, and Mexican Americans (42).	Association unclear
<i>Cys²⁶⁴ variant</i>		More common in African-Americans (22.5%) and Han-Chinese (11.7%) compared with Mexican Americans (5%) or Caucasian Americans (2.5%; ref. 42)	
<i>CBR311G>A</i>	Doxorubicin	Frequency of the A allele is 36% in Europeans, 47.5-57% in Chinese, and 27.3% in African-Americans (48, 120).	Associated with lower conversion of doxorubicin to doxorubicinol (48). Greater doxorubicin-induced myelosuppression has been observed in Chinese compared with Caucasians (47), although direct evidence of link with this polymorphism is still lacking.
<i>CDA 208G>A [Ala⁷⁰Thr]</i>	Gemcitabine	More common in Africans (13%) compared with Japanese (4.3%) or Europeans (0%; refs. 82, S3).	Association unclear
<i>SLC28A1 1561G>A</i>	Gemcitabine	More common in Caucasians (73%) compared with Chinese (12%), Malays (30%), or Indians (35%; ref. 84).	Association unclear
<i>DCK</i>	Gemcitabine	Asians have a higher allele frequency (15.6%) of this linked promoter polymorphism compared with Caucasians (2%; ref. 85).	Might predispose Asians to gemcitabine-associated toxicity but clinical association currently lacking.
<i>-C360G/-C201T</i>			

Reprinted with permission from Tan et al. (41, pp. 8028–8031).

IMPLICATIONS FOR TREATMENT AND RESEARCH

This paper is not the first to draw attention to the looming crisis of breast cancer as a global public

health issue. The mandate of Breast Health Global Initiative (57) is focused primarily on the planning side of cancer control, and includes the development of tailored recommendations for diagnosis, screening and treatment options for each of four economic tiers.

These guidelines are evidenced-based, but almost exclusively derive from studies of Caucasian women from high-income countries.

Promising new targeted agents, such as small molecule tyrosine kinase inhibitors and monoclonal antibodies such as trastuzumab, which targets breast cancer cells overexpressing her2neu, are rapidly making their way into general oncology practice in high-resource countries. These “smart bombs” of the oncology world will, no doubt, have increasing utility either as stand-alone or adjunct drugs in the armamentarium of anti-neoplastics. However, given the experience to date with cost of these agents, and the likelihood that any of these drugs will be off-patent and “genericized” in the coming decade, it is presently entirely beyond the reach of low and middle-resource countries to even consider their use. According to the WHO, a drug may be considered cost-effective if the annual cost per quality-adjusted life year saved, or QALY, is no greater than a country’s per capita GDP (gross domestic product) (58). China, a country undergoing tremendous economic growth, nonetheless had an estimated per capital GDP of \$5,300 in 2007. India’s per capita GDP was \$2,700 (59). Data on cost per quality-adjusted life year gained for trastuzumab range from \$~ 200,000 to \$50,000, illustrating the point that costs for targeted agents will be excessive for at least half of the world’s breast cancer patients who might benefit from this drug [60].

As the lion’s share of drug development budgets are focused on targeted agents, we are concerned that the developing world will be increasingly left behind. The “treatment gap” that already exists between high, middle and low-resource populations will widen, unless new approaches to affordable, effective and tolerable therapies are properly evaluated in the relevant populations.

We submit that our current understanding of breast cancer causation and biology in low and middle resource, non-Western and non-Caucasian populations is significantly limited. We are only beginning to investigate factors which influence breast cancer incidence and mortality, distribution of tumor subtypes, host metabolic and pharmacogenomic factors. We must resist the urge to extrapolate what is known from one population to another. Emerging data presented here should give us pause in considering how we approach breast cancer control in populations where we have minimal or no data.

To address the issue of global cancer control in a more rational fashion, we propose that clinical trials, along with translational correlative science should be supported in low and middle-resource countries. It is our contention that the scientific knowledge gained from truly international, collaborative research partnerships are best suited to improve breast cancer care in resource-poor populations, and at the same time aid in the development of better-tailored, cost-effective cancer prevention and management approaches for women in the developed world.

In this article, we have not addressed the broad political and health system challenges relevant in bringing to bear evidenced-based medicine to global breast cancer control. It is essential that we consider at every step the social and ethnocultural milieu in which women live. Our colleagues in the social sciences should be engaged early and often to provide much needed context.

REFERENCES

1. Random House Unabridged Dictionary, Copyright © 1997, by Random House, Inc.
2. Ferlay J, Bray F, Pisani P, Parkin DM. *GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide IARC Cancer Base No 5, version 2.0*. Lyon France: IARC Press, 2004.
3. Curado MP, Edwards B, Shin HR, *et al.*, eds. *Cancer Incidence in Five Continents*, Vol. IX IARC Scientific Publications No. 160. Lyon: IARC, 2007.
4. Hermon C, Beral V. Breast cancer mortality rates are leveling off or beginning to decline. *Br J Cancer* 1996;73:955–60.
5. Peto R. Mortality from breast cancer in the U.K. has decreased suddenly. *BMJ* 1998;317:476–8.
6. Peto R, Boreham J, Clarke M, Davies C, Beral V. U.K. and U.S.A. breast cancer deaths down 20–69 years. *Lancet* 2000; 355:18220.
7. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer mortality. *Br Ca Res Treat* 2004; 6:229–39.
8. Kanavos P. The rising burden of cancer in the developing world. *Ann Oncol* 2006;17(suppl 8):15–23.
9. IARC Working Group. *Handbook of Cancer Prevention*, Vol 7. Lyon France: IARC Press, 2002.
10. Stewart B, Kleigues PE. *World Cancer Report*. Lyon France: IARC Press, 2003.
11. Chia KS, Reilly M, Tan C-S, *et al.* Profound changes in breast cancer incidence may reflect changes into a westernised lifestyle: a comparative population-based study in Singapore and Sweden. *Int J Cancer* 2005;113:302–6.
12. Shen Y-C, Change C-J, Hsu C, Cheng C-C, Chiu C-F, Cheng A-L. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications for age-period-cohort analysis. *Cancer Epidemiol Biomarkers Prev* 2005;14:1986–90.
13. Sim X, Ali RA, Wedren S, *et al.* Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968–2002. *BMC Cancer* 2006;6:261.

14. World Cancer Research Fund, American Institute for Cancer Research. *Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective*. Washington DC: American Institute for Cancer Research, 2007.
15. Porter P. Westernizing women's risks? Breast cancer in low income countries. *N Engl J Med* 2008;358:213–6.
16. American Cancer Society. *Global Facts and Figures*. Atlanta: ACS, 2007.
17. Fackenthal JD, Olopade O. Breast cancer risk associated with BRCA1 and BRCA2 mutations in diverse populations. *Nat Rev Cancer* 2007;7:937–47.
18. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 2007;447:1087–94.
19. Ziegler R, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. *JNCI* 1993;85:1819–27.
20. Deapen D, Liu L, Perkins C, Bernstein L, Ross R. Rapidly rising breast cancer incidence rates among Asian-American women. *Int J Cancer* 2002;99:747–50.
21. Kato I, Tominaga S, Kuroishi T. Relationship between Western dietary habits and mortality from breast cancer, ovarian cancers in Japan. *Jpn J Cancer Res* 1987;78:349–57.
22. Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. *Epidemiol Rev* 1993;15:7–16.
23. Ursin G, Bernstein L, Pike MC. Breast cancer (Rev). *Cancer Surv* 1994;19–20:241–64.
24. Wu AH, Ziegler RG, Nomura AMY, et al. Soy intake and risk for breast cancer in Asians and Asian Americans. *Am J Clin Nutr* 1998;68(suppl):1437s–43s.
25. Horn-Ross PL, Lee M, John EM, Koo J. Sources of phytoestrogen exposure among non-Asian women in California, USA. *Cancer Causes Control* 2000;11:299–301.
26. Bilimoria KY, Winchester DP. The importance of worldwide cancer registration. *J Surg Oncol* 2008;97:481–2.
27. Olopade F, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. *Cancer Res* 2008;14:7987.
28. Pegoraro RJ, Karnan V, Nirmul D, Joubert SM. Estrogen and progesterone receptors in breast cancer among women of different racial groups. *Cancer Res* 1986;46(4 Pt 2):2117–20.
29. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. *Cancer Epidemiol Biomarkers Prev* 2002;11:601–7.
30. Uy GB, Laudico AV, Fernandez AM, et al. Immunohistochemical assay of hormone receptors in breast cancer at the Philippine General Hospital: importance of early fixation of specimens. *Philipp J Surg Spec* 2007;62:123–7.
31. Tran D, Lawson J. Rates of estrogen receptor-alpha expression are no different in low-risk (Vietnam) and high-risk (Australian) breast cancer. *Appl Immunohistochem Mol Morphol* 2004;12:139–41.
32. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–52.
33. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869–74.
34. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* 2003;100:8418–23.
35. Sotiropoulos C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc Natl Acad Sci U S A* 2003;100:10393–8.
36. Olopade OI, Ikpatt OF, Dignam JJ, et al. “Intrinsic gene expression” subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. *Proc Am Soc Clin Oncol* 2004;23:9509 (abstract).
37. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. *JNCI* 2005;97:439–48.
38. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. *JAMA* 2006;295:2492–502.
39. Bowen RL, Stebbing J, Jones LJ. A review of ethnic differences in breast cancer. *Pharmacogenomics* 2006;7:935–42.
40. Deeken JF, Figg WD, Bates SE, Sparreboom A. Towards individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. *Anticancer Drugs* 2007;18:11–17.
41. Tan S-H, Lee S-C, Goh B-C, Wong J. Pharmacogenetics in breast cancer therapy. *Clin Cancer Res* 2008;14:8027–41.
42. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of Tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. *J Clin Oncol* 2005;23:9312–8.
43. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant Tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. *J Clin Oncol* 2007;25:5187–93.
44. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. *Breast Cancer Res Treat* 2005;91:249–58.
45. Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. *Breast Cancer Res* 2005;7:R284–90.
46. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjöld B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. *Breast Cancer Res* 2007;9:R7.
47. Bradford LD. CYP2D6 allele frequencies in European Caucasians, Asian, Africans and their descendants. *Pharmacogenomics* 2003;3:229–43.
48. Ingelman-Sundberg M. Genetic polymorphism in cytochrome p450 2D6 (CYP 2D6): clinical consequences, evolutionary aspects, and functional diversity. *Pharmacogenomics J* 2005;5:6–13.
49. Lee EJ, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. *Br J Clin Pharmacol* 1994;37:605–7.
50. Garcia-Barcelo M, Chow LY, Chiu HF, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. *Clin Chem* 2000;46:18–23.
51. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. *Pharmacogenetics* 1996;6:441–7.
52. Yoon YR, Cha IJ, Shon JH, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. *Clin Pharmacol Ther* 2000;67:576.
53. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. *Br J Clin Pharmacol* 2000;50:31–34.
54. Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H. Clinical implications of CYP2D6 genotyping in

tamoxifen treatment for breast cancer. *Clin Cancer Res* 2009;15:15–21.

55. Beith JM, Goh BC, Yeo W, *et al.* Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. *Proc Am Soc Clin Oncol* 2002;21 [abstract 252].

56. Fan L, Goh BC, Wong CI, *et al.* Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. *Pharmacogenet Genomics* 2008;18:623–31.

57. Guidelines for International Breast Health and Cancer Control. Breast Health Global Initiative. *Cancer* 2008;113(S8):2215–371.

58. On line. <https://www.cia.gov/library/publications/the-world-factbook/> (accessed January 25, 2009)

59. Liberato NL, Marchetti M, Barosi G. Cost-effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2007;25:625–33 Available at: <http://www.who.int/en/> (accessed January 25, 2009).